Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)
October 20, 2021 07:12 AM EDTUpdated 10:28 AM
Pharma

Up­dat­ed: Bio­gen sells just $300K worth of Aduhelm in Q3, as ques­tions on long-term vi­a­bil­i­ty re­main

Zachary Brennan

Senior Editor

Bare­ly any­one is ac­cess­ing Bio­gen’s con­tro­ver­sial Alzheimer’s treat­ment, with the com­pa­ny re­port­ing just $0.3 mil­lion in Aduhelm sales in the third quar­ter. Al­though in­vestors will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times